Market Overview

Wall Street Initiates Coverage On Milacron Holdings

Share:

Milacron Holdings Corp (NYSE: MCRN) priced its initial public offering of ~14.286 million shares of common stock at the price of $20 on June 25. Shares declined calmly on its first day of trading, and have dropped nearly 14.38 percent since the IPO.

The plastic manufacturing equipment maker announced that it will report its first-ever quarterly earnings as a public company on August 11, before the opening bell.

Wall Street analysts got their hands on the stock and here is what they had to say:

  • Goldman Sachs: Initiated coverage with a Neutral rating alongside a price target of $19.00.
  • JP Morgan: Initiated with Neutral rating; price target of $20.00.
  • Bank of America Merrill Lynch: Initiated with Buy rating; price target of $23.00.
  • Barclays Capital: Initiated with Overweight rating; price target of $25.00
  • Credit Suisse: Initiated with Neutral rating; price target of $23.00.
  • Baird Capital: Initiated with Outperform rating; price target of $24.00.
  • KeyBanc: Initiated with Overweight rating; price target of $22.00.
  • William Blair: Initiated with Outperform rating.

SUMMARY: 3 Neutral, 2 Overweight, 2 Outperform, 1 Buy rating; price target range of $19-$25.

Latest Ratings for MCRN

DateFirmActionFromTo
Jul 2019DowngradesOutperformNeutral
Oct 2018MaintainsOverweightOverweight
Mar 2016MaintainsOutperform

View More Analyst Ratings for MCRN
View the Latest Analyst Ratings

Posted-In: Price Target Initiation Analyst Ratings

 

Related Articles (MCRN)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
DEReiterates175.0
AMWDMaintains92.0
FTDRMaintains55.0
REDUDowngrades
ZSDowngrades
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

An Update On Phase 3 ENSPIRIT Trial - Report on OncoGenex Pharmaceuticals

Why Two Wall Street Titans Love BioMarin Pharma